Pathophysiology of chronic heart failure;Fisiopatologia da insuficiência cardíaca crónica

Revista Portuguesa de Cardiologia

Volumn 28, Issue 4, 2009, Pages 439-471

  Seixas Cambão, Mariana ^b   Leite Moreira, Adelino F ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b NONE

Author keywords

Angiotensin; Autonomic nervous system; Cytokines; Dopaminergic system; Endothelin system; Heart failure; Natriuretic peptides; Neurohormones; Nitric oxide; Ventricular remodeling

Indexed keywords

ADRENOMEDULLIN; ALDOSTERONE; APELIN; ARGIPRESSIN; BRADYKININ; ENDOTHELIN; NATRIURETIC FACTOR; NITRIC OXIDE; PROSTAGLANDIN;

DISEASE COURSE; HEART FAILURE; HEART HYPERTROPHY; HEART OUTPUT; HEART STIMULATION; HEART VENTRICLE REMODELING; HEMODYNAMICS; HUMAN; HYPERTENSION; KIDNEY FAILURE; NONHUMAN; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM RETENTION; VASOCONSTRICTION; WATER RETENTION;

CARDIOMEGALY; CHRONIC DISEASE; HEART; HEART FAILURE; HEMODYNAMICS; HUMANS; INFLAMMATION; VASOCONSTRICTION; VENTRICULAR REMODELING; WATER-ELECTROLYTE BALANCE;

EID: 67649829844     PISSN: 08702551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (105)

1. Katz AM. Heart Failure: Pathophysiology, Molecular Biology and Clinical Management. Lippincott Williams & Williams, Philadelphia 2000.
2. Cerqueira Gomes M, Ferreira A, Bettencourt P. Fisiopatologia da Insuficiência Cardíaca. Rev Port Cardiol 2004;23(Supl.II):7-23. (Pubitemid 38922793)
3. Francis GS. Neuroendocrine activity in congestive heart failure. Am J Cardiol 1990;66:33D-39D. (Pubitemid 20352292)
4. Schrier RW, Abraham WT. Hormones and Hemodynamics in Heart Failure. N Engl J Med 1999; 341:577-585 (Pubitemid 29384167)
5. Karl T, Weber MD. Aldosterone in Congestive Heart Failure. N Engl J Med 2001;345(23): 1689-1697 (Pubitemid 33126826)
6. Pitt B, Zannand F, Remme W et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-717 (Pubitemid 29407370)
7. Mehra MR, Rockman HA, Greenberg BH. Highlights of the 2007 Scientific Meeting of the Heart Failure Society of America. J Am Coll Cardiol 2008;51(No3):320-327
8. De Bold AJ. Heart atria granularity. Effects of changes in water-electrolyte balance. Proc Soc Biol Med 1979;161:508-511
9. Bettencourt P, Azevedo A. Peptídeo Natriurético Tipo B. Papel na Fisiopatologia, Diagnóstico e Prognóstico da Insuficiência Cardíaca. Rev Port Cardiol 2004;23(Supl. II):95-104.
10. Nakagawa O, Ogawa Y, Itoh H, et al. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload. J Clin Invest 1995; 96(3):1280-1287.
11. Saito Y, Nakao K, Araiet H, et al. Augmented expression of atrial natriuretic polypeptide gene in ventricle of human failing heart. J Clin Invest 1989;83:298-305. (Pubitemid 19048436)
12. Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, Espiner EA. Immunoreactive aminoterminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol 1997; 47:287-296 (Pubitemid 27395959)
13. Ferreira S, Almeida R, Guerrero H, et al. Prognóstico na Insuficiência Cardíaca Descompensada: Papel do NT-proBNP. Rev Port Cardiol 2007; 28(5):535-545 (Pubitemid 47067555)
14. von Haehling S, Jankowska EA, Morgenthaler NG, et al. Comparison of Midregional Pro-Atrial Natriuretic Peptide With N-Terminal Pro-B-Type Natriuretic Peptide in Predicting Survival in Patients With Chronic Heart Failure. J Am Coll Cardiol 2007;50:1973-1980 (Pubitemid 350046336)
15. Touys RM, Schiffrin EL. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth cells. Pharmacol Rev 2000;52:639-672
16. Matsubara H. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res 1998;83:1182-1191
17. Castro-Chaves P, Leite-Moreira A F. Sistema Renina Angiotensina e seu Papel na Fisiopatologia e Terapêutica Cardiovascular. Rev Port Cardiol 2004;23(Supl. II):61-77.
18. Linz W, Wohlfart P, Scholkems BA, Malinski T, Wiemer G. Interactions among ACE, kinins and NO. Cardiov Res 1999;43:549-561 (Pubitemid 29369254)
19. Loot AE, Roks AJ, Henning RT, Tio RA, Suurmeijer AJ, Boomsma F, van Gilst WH. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation 2002;105:1548-1550
20. Ferrario CM. Does Angiotensin 1-7 contribute to cardiac adaptation and preservation of endothelial function in heart failure? Circulation 2002;105:1523-1525
21. De Gasparo M, Catt KJ, Wright JW, Unger TH. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000;52:415-472
22. Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002;360:752-760
23. Bissessor N, White H. Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction. Vasc Health Risk Manag 2007;3(4):425-430 (Pubitemid 47553491)
24. Teerlink JR. Reversal of left ventricular remodeling: Role of the endothelin pathway. J Card Fail, 2002; 8: S494-99. (Pubitemid 36083103)
25. Hulsmann M, Stanek B, Frey B, et al. Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure. J Am Coll Cardiol 1998;32:1695-1700 (Pubitemid 28545210)
26. EL-Menyar AA. Cytokines and Myocardial Dysfunction: State of the Art. J Card Fail 2008;14:61-74.
27. Galtius-Jensen S, Wroblewski H, Emmeluth C, Bie P, Haunso S, Kastrup J. Plasma endothelin in congestive heart failure: a predictor of cardiac death? J Card Fail 1996;2:71-76
28. Leite-Moreira AF, Brás-Silva C. Inotropic effects of ETB receptor stimulation and their modulation by endocardial endothelium, NO, and prostaglandins. Am J Physiol (Heart Circ Physiol) 2004; 287:H1194-9. (Pubitemid 39096666)
29. Leite-Moreira AF, Brás-Silva C. Modulação dos Efeitos Miocárdicos da Estimulação Selectiva dos Receptores ETB e suas Implicações na Insuficiência Cardíaca. Rev Port Cardiol 2005; 24(9):1125-1133 (Pubitemid 41674252)
30. Tatemoto K, Hosoya M, Habata Y, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 1998;251(2):471-476 (Pubitemid 28505047)
31. Chen MM, Ashley EA, Deng DX, et al. Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. Circulation 2003;108:1432-1439 (Pubitemid 37176447)
32. Falcão-Pires I, Leite-Moreira AF. Apelina: Um Novo Modulador Neurohumoral do Aparelho Cardiovascular. Rev Port Cardiol 2005; 24(10):1263-1276. (Pubitemid 41774929)
33. Ishida J, Hashimoto T, Hashimoto Y, et al. Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin type 1 receptor in blood pressure in vivo. J Biol Chem 2004;279(25):26274-26279 (Pubitemid 38798776)
34. Vickers C, Hales P, Kaushik V, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 2002;277(17):14838-14843 (Pubitemid 34952556)
35. Szokodi I, Tavi P, Foldes G, et al. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res 2002;91(5):434-440 (Pubitemid 35034212)
36. Foldes G, Horkay F, Szokodi I, et al. Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. Biochem Biophys Res Commun 2003;308(3):480-485 (Pubitemid 36945517)
37. Brás-Silva C, Leite-Moreira AF. O Óxido Nítrico na Fisiopatologia da Disfunção Miocárdica na Insuficiência Cardíaca. Rev Port Cardiol 2004;23(Supl II):105-119
38. Hare JM, Givertz MM, Creager MA, Colucci WS. Increased sensitivity to nitric oxide inhibition in patients with heart failure. Potentiation of β-adrenergic inotropic responsiveness. Circulation 1998; 97:161-166.
39. Heymes C, Vanderheyden M, Bronzwaer JG, Shah AM, Paulus WJ. Endomyocardial nitric oxide synthase and left ventricular preload reserve in dilated cardiomyopathy. Circulation 1999; 99:3009-3016 (Pubitemid 29270430)
40. Drexler H, Kastner S, Strobel A, Studer R, Brodde OE, Hasenfuss G. Expression, activity and functional significance of inducible nitric oxide synthase in the failing human heart. J Am Coll Cardiol 1998;32:955-963 (Pubitemid 28459584)
41. Shah AM, MacCarthy PA. Paracrine and autocrine effects of nitric oxide on myocardial function. Pharmacol Ther 2000;86:49-86. (Pubitemid 30173144)
42. Pacher P, Beckman JS, Liaudet L. Nitric Oxide and Peroxynitrite in Health and Disease. Physiol Rev 2007;87:315-424.
43. Hirooka Y, Imaizumi T, Tagawa T, et al. Effects of L-arginine on impaired acetylcholine-induced and ischemic vasodilatation of the forearm in patients with heart failure. Circulation. 1994;90:658-668.
44. Kitamura K, Kangawa K, Kawamoto M, et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 1993;192:553-560 (Pubitemid 23227359)
45. Kitamura K, Sakata J, Kangawa K., Kojima M, Matsuo H, Eto T. Cloning and characterization of cDNA encoding a precursor for human adrenomedullin. Biochem Biophys Res Commun 1993;194:720-725 (Pubitemid 23245195)
46. Nagaya N, Satoh T, Nishikimi T, et al. Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure. Circulation 2000;101:498-503. (Pubitemid 30080863)
47. Ishimitsu T, Ono H, Minami J, Matsuoka H. Pathophysiologic and therapeutic implications of adrenomedullin in cardiovascular disorders. Pharmacology & Therapeutics 111 2006; 909-927. (Pubitemid 44118439)
48. Ihara T, Ikeda U, Tate Y, Ishibashi S, Shimada K. Positive inotropic effects of adrenomedullin on rat papillary muscle. Eur J Pharmacol 2000;390:167-172. (Pubitemid 30122450)
49. Ishimitsu T, Minami J, Nishikimi T, et al. Changes in plasma adrenomedullin in physiological and pathological conditions in human subjects. J Cardiovasc Pharmacol 1999;34 (Suppl. 4):S47-S51.
50. Pousset F, Masson F, Chavirovskaia O, et al. Plasma adrenomedullin, a new independent predictor of prognosis in patients with chronic heart failure. Eur Heart J 2000;21:1009-1014 (Pubitemid 30312090)
51. Nishikimi T, Yoshihara F, Horinaka S, et al. Chronic administration of adrenomedullin attenuates transition from left ventricular hypertrophy to heart failure in rats. Hypertension 2003; 42:1034-1041 (Pubitemid 37413749)
52. Nishikimi T, Matsuoka H. Cardiac Adrenomedullin: Its Role in Cardiac Hypertrophy and Heart Failure. Curr Med Chem Cardiovasc Hematol Agents 2005; 3:231-242
53. Dzau VJ, Packer M, Lilly LS, et al. Prostaglandins in severe congestive heart failure. Relation to activation of the renin-angiotensin system and hyponatremia. N Engl J Med 1984;310:347-352 (Pubitemid 14179539)
54. Wu KK. Cyclooxygenase-2 induction in congestive heart failure. Friend or foe? Circulation 1998;98:95-96.
55. Esler M, Kaye D, Lambert G, Esler D, Jennings G. Adrenergic nervous system in heart failure. Am J Cardiol 1997;80(11A):7L-14L. (Pubitemid 27528443)
56. Bristow MR. β-adrenergic receptor blockade in chronic heart failure. Circulation 2000;101: 558-569 (Pubitemid 30080872)
57. Ferreira A. As Citocinas na Insuficiência Cardíaca. Rev Port Cardiol 2004;23(Supl.II):121-127.
58. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334(21): 1349-1355
59. Cohn JN, Levine B, Olivari MT et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Eng J Med 1984;311:819-823 (Pubitemid 14035089)
60. Diwan A, Tran T, Misra A, Mann DL. Inflammatory mediators and the failing heart: a translational approach. Curr Mol Med 2003;3:161-182 (Pubitemid 36285104)
61. Jankowska EA, Ponikowski P, Piepoli MF, Banasiak W, Anker SD, Poole-Wilson PA. Autonomic imbalance and immune activation in chronic heart failure - Pathophysiological links. Cardiovascular Research 2006;70(3):434-445
62. Sartori C, Lepowi M, Scherrer U. Interaction between nitric oxide and the cholinergic and sympathetic nervous system in cardiovascular control in humans. Pharmacol Ther 2005;106:209-220 (Pubitemid 40603865)
63. Dzau VJ. Renal and circulatory mechanisms in congestive heart failure. Kidney Int 1987;31:1402-1415 (Pubitemid 17090506)
64. Ferreira A, Bettencourt P, Pimenta J, et al. The renal dopaminergic system, neurohumoral activation, and sodium handling in heart failure. Am Heart J 2002;143:391-397 (Pubitemid 34185168)
65. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;223:236-241 (Pubitemid 20225044)
66. Torre-Amione G, Kapadia S, Lee J, et al. Tumor necrosis factor-a and tumor necrosis factor receptors in the failing human heart. Circulation 1996;93:704-711 (Pubitemid 26052456)
67. Aukrust P, Gullestad L, Lappegard KT, et al. Complement activation in patients with congestive heart failure. Circulation 2001;104:1494-1500
68. Nishimura Y, Inoue T, Nitto T, Morooka T, Node K. Increased interleukin-13 levels in patients with chronic heart failure. Int J Cardiol 2007, doi:10.1016/j.ijcard.2007.07.128.
69. Torre-Amione G. Immune activation in chronic heart failure. Am J Cardiol 2005;95:3C-8C. (Pubitemid 40755512)
70. Meldrum DR. Tumor necrosis b factor in the heart. Am J Physiol 1998; 274: R577. (Pubitemid 28158306)
71. Prabhu S. Cytokine-modulation of cardiac function. Circ Res 2004; 95:1140-1153
72. Rauchhaus M, Doehner W, Francis DP, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000;102:3060-3067
73. Tanner H, Mohacsi P, Fuller-Bicer GA et al. Cytokine Activation and Disease Progression in Patients With Stable Moderate Chronic Heart Failure. J Heart Lung Transplant 2007; 26:622-629 (Pubitemid 46818035)
74. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996;27:1201-1206 (Pubitemid 26117714)
75. Suzuki S, Takeishi Y, Niizeki T et al. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J 2008;155:75-81. (Pubitemid 350234768)
76. Negoro S, Oh H, Tone E, et al. Glycoprotein 130 regulates cardiac myocyte survival in doxorubicin-induced apoptosis through phosphatidylinositol 3-kinase/Akt phosphorylation and Bcl-xL/caspase-3 interaction. Circulation 2001;103: 555-561 (Pubitemid 32116241)
77. Mann DL. Recent insights into the role of tumor necrosis factor in the failing heart. Heart Fail Rev 2001;6:71-80. (Pubitemid 32328170)
78. Niebauer J, Volk HD, Kemp M, et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 1999;353:1838-1842 (Pubitemid 29251016)
79. Hartog JWL, Voors AA, Bakker SJL, Smit AJ, van Veldhuisen DJ. Advanced glycation end-products (AGEs) and heart failure: Pathophysiology and clinical implications. Eur J Heart Fail 2007;9:1146-1155 (Pubitemid 350138497)
80. Sadoshima J, Izumo S. The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol 1997; 59:551-571 (Pubitemid 27142455)
81. Hunter JJ, Chien KR. Signaling Pathways for Cardiac Hypertrophy and Failure. N Eng J Med 1999; 341:1276-1283. (Pubitemid 29489744)
82. Chien KR. Meeting Koch's postulates for calcium signaling in cardiac hypertrophy. J Clin Invest 2000;105:1339-1342 (Pubitemid 30322398)
83. Gonçalves LM. Mecanismos Fisiopatológicos da Remodelagem Ventricular. Rev Port Cardiol 2004; 23 (Supl.II):41-46.
84. Bueno OF, Molkentin JD. Involvement of extracellular signal-regulated kinases 1/2 in cardiac hypertrophy and cell death. Circ Res 2002;91:776-781 (Pubitemid 35285074)
85. Towbin JA. Scarring in the Heart - A Reversible Phenomenon? N Eng J Med 2007;357:1767-1768
86. Gupta S, Young D, Maitra RK et al. Prevention of Cardiac Hypertrophy and Heart Failure by Silencing of NF-κB. J Mol Biol 2008; 375:637-649
87. Ruiz-Ortega M, Lorenzo O, Ruperez M, Konig S, Witting B, Egido J. Angiotensin II activates nuclear transcription factor-kB through AT-1 and AT-2 in vascular smooth muscle cells: molecular mechanisms. Circ Res 2000;86:1266-1272 (Pubitemid 30436668)
88. Sil P, Misono K, Sen S. Myotrophin in human cardiomyopathic heart. Circ Res 1993;73:98-108. (Pubitemid 23173060)
89. Matsui Y, Takagi H, Qu X, et al. Distinct roles of autophagy in the heart during ischemia and reperfusion: roles of AMP-activated protein kinase and Beclin-1 in mediating autophagy. Circ Res 2007;100:914-922 (Pubitemid 46555697)
90. Zhu H, Tannous P, Johnstone JL, et al. Cardiac autophagy is a maladaptative response to hemodynamic stress. J Clin Invest 2007;117:1782-1793 (Pubitemid 47036312)
91. Jessup M, Brozena S. Heart Failure. N Engl J Med 2003;348:2007-2018
92. Hill JA, Olson EN. Cardiac Plasticity. N Eng J Med 2008;358:1370-1380
93. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling - Concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol 2000;35:569-582 (Pubitemid 30167013)
94. Zeisberg EM, Tarnavaski O, Zeisberg M, et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 2007;13:952-961 (Pubitemid 47222040)
95. Roncon-Albuquerque R Jr, Leite-Moreira AF. Cinética do Cálcio na Progressão da Insuficiência Cardíaca. Rev Port Cardiol 2004;23(Supl. II):25-44.
96. del Monte F, Harding SE, Schmidt U, et al. Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation 1999;100:2308-2311
97. Miyamoto MI, del Monte F, Schmidt U, et al. Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci USA 2000;97:793-798 (Pubitemid 30070389)
98. Diedrichs H, Chi M, Boelck B, Mehlhorm U, Schwinger RH. Increased regulatory activity of the calcineurin/NFAT pathway in human heart failure. Eur J Heart Fail 2004;6:3-9. (Erratum, Eur J Heart Fail 2004;6:823.) (Pubitemid 38169598)
99. Bers DM. Calcium fluxes involved in control of cardiac myocyte contraction. Circ Res 2000;87:275-281 (Pubitemid 30655967)
100. Dipla K, Mattiello JA, Margulies KB, Jeevanandam V, Houser SR. The sarcoplasmic reticulum and the Na+/Ca2+ exchanger both contribute to the Ca2+ transient of failing human ventricular myocytes. Circ Res 1999;84:434-444 (Pubitemid 29120009)
101. Sipido KR, Volders PG, Vos MA, Verdonck F. Altered Na/Ca exchange activity in cardiac hypertrophy and heart failure: a new target for therapy? Cardiovasc Res 2002;53:782-805.
102. Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA. Controversies in ventricular remodelling. Lancet 2006;367:356-367
103. Berenji K, Drazner MH, Rothermel BA, Hill JA. Does load-induced ventricular hypertrophy progress to systolic heart failure? Am J Physiol Heart Circ Physiol 2005;289:H8-H16.
104. Fazio S, Palmieri EA, Affuso F, et al. Effects of growth hormone on exercise capacity and cardiopulmonary performance in patients with chronic heart failure. J Clin Endocrinol Metab 2007;92:4218-4223 (Pubitemid 350074734)
105. Pacher P, Beckman J S, Liaudet L. Nitric Oxide and Peroxynitrite in Health and Disease. Physiol Rev 2007;87:315-424.